Treat-and-Extend Intravitreal Bevacizumab for Branch Retinal Vein Occlusion
Ophthalmic Surgery, Lasers and Imaging Retina, 2014 BACKGROUND AND OBJECTIVE: To determine the effectiveness and direct medical costs of treat-and-extend (TAE) intravitreal bevacizumab (IVB) for the treatment of branch retinal vein occlusion (BRVO)–associated macular edema (ME). PATIENTS AND METHODS: Retrospective chart review of 52 ...
Rush, R +3 more
openaire +3 more sources
Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study [PDF]
British Journal of Ophthalmology, 2015 To demonstrate non-inferiority of ranibizumab treat-and-extend (T&E) with/without laser to ranibizumab pro re nata (PRN) for best-corrected visual acuity (BCVA) in patients with diabetic macular oedema (DMO).A 24-month single-masked study with patients randomised 1:1:1 to T&E+laser (n=121), T&E (n=128) or PRN (control; n=123).
Prunte C. +10 more
openaire +3 more sources
Results of a Treat-and-Extend Regimen of Intravitreal Ranibizumab Injection for Macular Edema due to Branch Retinal Vein Occlusion [PDF]
, 2018 To investigate the effectiveness of a treat-and-extend regimen (TAE) of intravitreal ranibizumab injections (IVR) for macular edema (ME) due to branch retinal vein occlusion (BRVO).
Doi, Shinichiro +11 more
core +1 more source
Morphologic Criteria of Lesion Activity in Neovascular Age-Related Macular Degeneration: A Consensus Article [PDF]
, 2017 Intravitreal antivascular endothelial growth factor drugs represent the current standard of care for neovascular age-related macular degeneration (nAMD).
Elena Gusson +8 more
core +1 more source
Association Between Visual Acuity and Fluid Compartments with Treat-and-Extend Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: An ARIES Post Hoc Analysis. [PDF]
, 2022 INTRODUCTION Recently, there has been growing interest in exploring the relationship between visual acuity and fluid localization in different retinal compartments.
Allmeier, Helmut +8 more
core +1 more source
Optimizing the Anti-VEGF Treatment Strategy for Neovascular Age-Related Macular Degeneration: From Clinical Trials to Real-Life Requirements. [PDF]
, 2015 This Perspective discusses the pertinence of variable dosing regimens with anti-vascular endothelial growth factor (VEGF) for neovascular age-related macular degeneration (nAMD) with regard to real-life requirements.
Mantel, I.
core +1 more source
Ophthalmology and Therapy, 2020 Introduction To evaluate 1-year outcomes of intravitreal aflibercept (IVA) using a treat-and-extend (TAE) regimen for polypoidal choroidal vasculopathy (PCV) and identify the factors for patients whose treatment intervals could be extended. Methods Fifty-
Tomoko Tamachi +8 more
doaj +1 more source
Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept. [PDF]
, 2017 The purpose of our study was to investigate the two-year outcome of Aflibercept treatment for neovascular age-related macular degeneration (nAMD), using the Observe-and-Plan regimen, an individually planned treatment regimen, based on the predictability ...
Ambresin, A. +4 more
core +1 more source
International Journal of Retina and Vitreous, 2019 Background To determine whether aflibercept (Eylea; Regeneron Pharmaceuticals, Inc., Tarrytown, NY) could continue to extend the macular edema free interval in patients on a treat and extend (TAE) with non-ischemic central retinal vein occlusions (CRVOs)
Rahul N. Khurana +5 more
doaj +1 more source
EXIT STRATEGY IN A TREAT-AND-EXTEND REGIMEN FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION [PDF]
Retina, 2019 Purpose: To evaluate the outcome of an exit strategy in a treat-and-extend regimen for neovascular age-related macular degeneration. Methods: Five hundred and ninety-eight eyes of 488 patients with neovascular age-related macular degeneration receiving intravitreal anti–vascular ...
Arendt, Petra +5 more
openaire +2 more sources